Latest

Ozempic

·July 29, 2026·8 min read

Oral Ozempic Cuts Heavy Drinking and Cravings

Oral semaglutide reduces heavy drinking days, daily cravings, and alcohol-related problems in adults with Alcohol Use Disorder.

Featured Neuroscience Psychology

·July 16, 2026·13 min read

GLP-1’s Reduce Binge Eating Symptoms

A new study establishes that GLP-1 receptor agonists significantly reduce core behavioral markers of Binge Eating Disorder, including active binge episodes, loss-of-control eating, and emotional eating.

Featured Neuroscience Visual Neuroscience

·July 14, 2026·10 min read

GLP-1s Linked to Sudden, Rare Vision Loss

Researchers identifies a slight statistical association between GLP-1 receptor agonists (including semaglutide and tirzepatide) and an increased risk of ischemic optic neuropathy.

Featured Neurology Neuroscience

·June 14, 2026·11 min read

GLP-1s Linked to Low Blood Pressure and Fainting Spikes

Adults taking GLP-1 receptor agonists alongside multiple blood pressure medications experience a significant increase in hypotensive events, including severe dizziness, fainting, and falls.

This shows a person running and a brain.

Featured Neuroscience

·June 13, 2026·8 min read

GLP-1 Therapies Silence Spontaneous Physical Activity

A new study demonstrates that adults managing obesity significantly decrease their physical activity after starting GLP-1 receptor agonist medications.

This shows a brain made of gut bacteria.

Featured Neuroscience Psychology

·June 10, 2026·9 min read

GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria

The GLP-1 agonist liraglutide treats depressive symptoms via a novel microbial pathway.

Featured Neuroscience

·May 22, 2026·8 min read

Study Aims to Break GLP-1 Weight-Loss Plateaus

The weight-loss effects of semaglutide depend on boosting a signaling molecule called cAMP within appetite-regulating neurons in the area postrema.

Featured Neurology Neuroscience

·April 23, 2026·8 min read

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.

This shows a woman on a scale with people pointing at her.

Featured Neuroscience Psychology

·April 17, 2026·8 min read

Decoding the Shame Associated with Ozempic Weight Loss

Women using GLP-1 drugs for weight loss face higher levels of stigma than those using diet and exercise, with many critics viewing the medication as a "shortcut."

Featured Genetics Neuroscience

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.